Mice deficient in pituitary adenylate cyclase activating polypeptide (PACAP) show increased susceptibility to in vivo renal ischemia/reperfusion injury.

@article{Szakly2011MiceDI,
  title={Mice deficient in pituitary adenylate cyclase activating polypeptide (PACAP) show increased susceptibility to in vivo renal ischemia/reperfusion injury.},
  author={P{\'e}ter Szak{\'a}ly and Eszter L{\'a}szl{\'o} and Krisztina Kov{\'a}cs and B{\'o}gl{\'a}rka R{\'a}cz and Gabriella Horvath and Andrea Ferencz and Andrea Lubics and P{\'e}ter Kiss and Andrea Tamas and R{\'e}ka Brubel and Balazs Opper and A. Ramesha Baba and Hitoshi Hashimoto and J{\'o}zsef Farkas and Attila Matkovits and Tam{\'a}s Magyarlaki and Zsuzsanna Helyes and Dora Reglodi},
  journal={Neuropeptides},
  year={2011},
  volume={45 2},
  pages={113-21}
}
Pituitary adenylate cyclase activating polypeptide (PACAP) is a neuropeptide with well-known cytoprotective effects. We have reported earlier that PACAP decreases mortality and the degree of tubular atrophy in a rat model of renal ischemia/reperfusion injury. Recently, we have shown that kidney cultures isolated from PACAP deficient mice show increased… CONTINUE READING